CD8A and melanoma: When LPS was combined with the differentiation TAA gp100 and the interleukin-2 (IL-2) receptor (IL-2R) agonist, IL-2/CD25 transdimers, gp100-specific melanoma-reactive Pmel-1 CD8+ T cell expansion, T cell memory formation, and antitumor responses to the B16-F10 mouse melanoma were enhanced to substantially extend mouse survival.